3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Pancreatic Neoplasms
17
Carcinoma, Non-Small-Cell Lung
9
Triple Negative Breast Neoplasms
8
Lung Neoplasms
7
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasm Metastasis
4
Biliary Tract Neoplasms
4
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Esophageal Squamous Cell Carcinoma
3
Stomach Neoplasms
2
Pancreatic Adenocarcinoma
2
Ovarian Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Cholangiocarcinoma
2
Advanced Solid Tumor
2
Uterine Cervical Neoplasms
1
Squamous Cell Non-small Cell Lung Cancer
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Neoplasms, Basal Cell
1
Muscle-Invasive Bladder Carcinoma
1
Metastatic Pancreatic Ductal Adenocarcinoma
1
Metastatic Pancreatic Adenocarcinoma
1
Melanoma, Cutaneous Malignant
1
Lymphoma
1
Locally Advanced or Metastatic Solid Tumors
1
Locally Advanced Pancreatic Cancer
1
Interventions
relatlimab
1
pembrolizumab
1
lifileucel
1
Temozolomide
1
Paclitaxel
1
Opdualag
1
Nivolumab
1
Ipilimumab
1
Eye Movement Desensitization Reprocessing
1
Dacarbazine
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Melanoma, Cutaneous Malignant
×
Albumin-Bound Paclitaxel
×
Clear all
NCT06743126
2026-05-29
SUPRAME
Immatics US, Inc.
Phase 3
Recruiting
360 enrolled